Acute effect of empagliflozin on serum uric acid - a subanalysis of the EMPAG-HF trial (effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure)

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Jurgen Bogoviku

University hospital Jena, Jena (Germany)

4 More presentations in this session

Presentation thumbnail

Dapagliflozin utilization following hospitalization for heart failure: real-world insights from EVOLUTION HF, a multinational, observational study

Associate Professor G. Savarese (Stockholm, SE)

Abstract Slides

Presentation thumbnail

Direct effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Doctor C. Andersen (Herlev, DK)

Abstract Slides

Presentation thumbnail

Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure

Doctor E. Kim (Seoul, KR)

Abstract Slides

Presentation thumbnail

Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

Professor M. Boehm (Homburg, DE)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - Pharmacotherapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources